SAN CARLOS, CA — Sift Biosciences is proud to announce that it has been selected to present at the 3rd Annual MBC BioLabs Oncology Forum, a curated gathering of early-stage oncology companies, investors, and pharmaceutical partners hosted by MBC BioLabs in San Carlos.
The Oncology Forum spotlights promising early-stage companies developing next-generation cancer therapeutics, from novel modalities and target classes to platform technologies advancing the future of oncology drug discovery.
“The MBC BioLabs Oncology Forum brings together some of the most exciting science and the most engaged partners in oncology drug development today,” said Dr. Yue Clare Lou, Co-Founder and CEO of Sift Biosciences. “We’re honored to share our progress on the SIFT™ platform alongside this group and look forward to the conversations that come out of it.”
Read Dr. Lou’s full announcement on LinkedIn.
About Sift Biosciences
Sift Biosciences is a preclinical immunotherapy company developing immunomodulators that harness pre-existing memory T-cells to treat immune dysfunctions. Founded in 2024 as a UC Berkeley spin-out, Sift integrates AI and high-throughput T-cell screening to mine billions of microbial proteins for motifs that activate antimicrobial memory T-cells and steer them toward tumor antigens, autoantigens, and other disease-relevant targets. The company’s initial focus is on oncology, with expanding pipelines in autoimmunity and immunosenescence.